ADVM - Avrobio Magenta Collaboration And Other News: The Good Bad And Ugly Of Biopharma
Avrobio Collaborates with Magenta Therapeutics for Advancing Novel ADC
Avrobio Inc. (AVRO) announced its latest collaboration with Magenta Therapeutics (MGTA) for advancing the latter's lead drug candidate MGTA-117. The tie-up will provide synergies for both the companies as Avrobio provides its expertise in lentiviral gene therapies while Magenta offers proficiency in ADC-based conditioning. The companies will jointly assess MGTA-117 in conjunction with one or more of Avrobio's investigational gene therapies.
MGTA-117 is a CD117-targeted antibody engineered for the transplant setting and is conjugated to amanitin. The drug candidate aims to specifically